Previous Article | Next Article 
Journal of Virology, November 1998, p. 9323-9328, Vol. 72, No. 11
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Epstein-Barr Virus Small RNA (EBER) Genes:
Differential Regulation during Lytic Viral Replication
Norbert
Greifenegger,1
Michael
Jäger,1
Leoni A.
Kunz-Schughart,2
Hans
Wolf,1 and
Fritz
Schwarzmann1,*
Institut für Medizinische Mikrobiologie
und Hygiene1 and
Institut für
Pathologie,2 Universität Regensburg,
Regensburg, Germany
Received 1 May 1998/Accepted 11 August 1998
 |
ABSTRACT |
In every latently Epstein-Barr virus-infected cell the viral genes
EBER-1 and EBER-2 are transcribed by polymerase III. In lytically
infected cells in vivo the EBER genes could not be detected. However,
in cell culture downregulation could not be confirmed, and hence the
relevance of this shutdown to the replication of the virus was not
clear. We assayed the transcriptional activity of the EBER genes by
nuclear run-on assays with enriched lytically infected cells and
demonstrated that EBER-1 and EBER-2 are differentially downregulated on
the transcriptional level during the switch to lytic viral replication.
This downregulation was an early event during the lytic replication of
the virus.
 |
TEXT |
During latency of the Epstein-Barr
virus (EBV), up to 11 viral genes are expressed that encode up to nine
proteins. Two of these genes, EBER-1 and EBER-2 (for a review, see
reference 3), are transcribed by polymerase III
(9). The transcripts are 167 and 172 bp in length,
respectively, have neither a 5' cap nor a 3' poly(A) tail, show
extensive secondary structure, and obviously do not encode proteins.
Due to the large number (up to 107) of copies per cell
(11), these RNAs are the most abundant transcripts in
latently EBV-infected cells.
The function of these viral RNAs is unclear. In different reports on
the localization of the EBERs, these RNAs were found either in the
nucleus (10) or near the nuclear membrane in the cytoplasm
(18), obviously tightly associated with the polyribosomes. On the basis of the homology of these RNAs to the small untranslated RNAs VAI and VAII of adenovirus (15), a highly plausible
role for the EBERs is the modulation of interferon-mediated antiviral responses by binding to and inactivation of the interferon-induced DAI
kinase (19-21). Furthermore, binding of the EBERs to
ribosomal protein L22 was shown (23), suggesting a role in
the regulation of translation. Finally, a mitogenic effect of the EBERs
was described when these RNAs were transiently expressed in primary B
cells, leading to an increase in protein synthesis (26).
The EBERs were found to be transcribed in every latently infected cell.
Reports on expression during lytic replication, however, are
controversial. In all cases of oral hairy leukoplakia (5) and in some cases of nasopharyngeal carcinoma (25) in which lytic replication of EBV was detected, no EBERs could be demonstrated by in situ hybridization. Similar results were reported in some cases
of well-differentiated squamous cell carcinoma with EBV latency type II
(13). Recently, we reported a case of chronic active EBV
infection in which the EBV-positive lymphocytes in the peripheral blood
were EBER negative (12). However, in cell culture induction
of viral lytic replication by phorbol 12-myristate 13-acetate (TPA) and
butyric acid (BA) did not result in a reduction of the EBERs when
assayed by Northern blot analysis (8, 24). Therefore, it
remained unclear whether the absence of the EBERs in some situations in
vivo was related to pathogenesis or to a principal mechanism of the
lytic cycle.
In this study we employed a new experimental approach in cell culture
to clarify whether the expression of the EBER genes is regulated during
the switch from latency to lytic viral replication. We performed
nuclear run-on assays to measure the actual activity of the EBER genes
in order to preclude a masking effect of stable EBERs derived from the
latent phase. To avoid falsification of the results by contaminating
latent cells, which transcribe vast amounts of EBERs, we enriched the
population of lytically infected cells.
Induction of lytic replication of EBV.
We tested several
methods of chemical treatment for their abilities to induce lytic
replication of EBV in cell culture. The cells were diluted with fresh
medium to a concentration of 5 × 106/ml, and 24 h later TPA (final concentration, 40 ng/ml) and BA (final
concentration, 3 mM) or transforming growth factor
(TGF-
) (final
concentration, 50 µl/ml, activated from fetal calf serum by
incubation with 1/10 volume of 2 N NaOH and neutralization with 2 N
HCl) or 5-iodo-2'-deoxyuridine (IUdR) (final concentration, 50 µg/ml), either individually or in combination (1), were added and incubated for up to 72 h. In Fig.
1 the abilities of the different
chemicals to induce lytic replication of EBV in the Burkitt's
lymphoma-derived cell line P3HR1/13 are shown. The proportion of cells
entering lytic replication of EBV was measured with
immunohistochemistry (Fig. 1A), immunofluorescence assays (Fig. 1B),
and fluorescence-activated cell sorting (FACS) (Fig. 1C) with the
monoclonal antibody BZ1 (Dako, Hamburg, Germany), specific for Zta
(ZEBRA, gene product of BZLF-1), and the monoclonal antibody mab-64D7
(cell culture supernatant, ammonium sulfate precipitated and
concentrated 10-fold in phosphate-buffered saline [PBS]), specific
for the late-lytic-cycle membrane protein gp350/220 (the product of the
BLLF-1 gene). Western blotting and immunohistochemistry detected
increasing expression of both viral proteins 24 to 72 h after
induction (Fig. 1A). Expression of gp350/220 was strongest after
72 h of treatment with TPA, BA, and TGF-
(lanes 13 and 16).
Immunofluorescence assays (Fig. 1B, lanes 13 and 16) and FACS (Fig. 1C)
confirmed these results, demonstrating approximately 40% of the cells
in the late lytic cycle expressing gp350/220 (upper right quadrant of
each panel). Hence, for the experiments described below the cells were
treated for 72 h with a combination of TPA, BA, and TGF-
.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 1.
Percentage of lytically infected P3HR1/13 cells induced
by various chemical treatments. P3HR1/13 cells were treated with TPA-BA
(lanes 1, 7, and 13), IUdR (lanes 2, 8, and 14), TGF- (lanes 3, 9, and 15), TPA-BA-TGF- (lanes 4, 10, and 16), IUdR-TGF- (lanes
5, 11, and 17), or TPA-BA-IUdR-TGF- (lanes 6, 12, and 18), and
the percentage of lytically infected cells was assayed after 24, 48, and 72 h. (A) 5 × 105 cells were harvested at
each time point, protein extracts were examined by polyacrylamide gel
electrophoresis and Western blotting, and Zta and gp350/220 were
detected with monoclonal antibodies. The gp350/220-specific monoclonal
antibody mab-64D7 yielded a double band that always migrated more
quickly than the standard, probably because of heavy glycosylation. (B)
Immunofluorescence assay. The percentage of gp350/220-positive cells is
indicated. (C) 5 × 105 cells were harvested at each
time point and analyzed by FACS with the gp350/220-specific monoclonal
antibody mab-64D7. The cells in the upper right quadrant of each panel
were considered positive; those in the lower right quadrant were
considered negative. Left panels: C1, untreated DG75; C3, latent
P3HR1/13; right panels: C2, chemically treated DG75; C4, treated
P3HR1/16. The percentage of gp350/220-positive cells is indicated in
the panels. The x axis indicates forward light scatter
(FSC); the y axis indicates the intensity of
gp350/220-specific fluorescence (FL1).
|
|
Purification of cells with lytic replication of EBV.
In order
to enrich the population of cells with lytically replicating EBV, the
viral glycoprotein gp350/220 was used as a physical marker on the cell
surface for purification. Separation and purification by FACS or by use
of magnetic Dynabeads were not suitable owing to great physical stress
leading to damage of the cells, which had already been stressed by the
chemical treatment and the lytic replication of the virus. Finally, we succeeded with the MACS system (Miltenyi Biotech, Bergisch Gladbach, Germany) and adjusted the protocol of the manufacturer to our particular situation of working with fragile lytically replicating EBV-infected cells. A quantity (5 × 107) of cells,
treated as described above to induce lytic replication of EBV, was
pelleted at 350 × g for 10 min at room temperature (RT) and washed twice with PBS-MACS (PBS [without Ca2+ or
Mg2+] with 0.5% bovine serum albumin and 2 mM EDTA, pH
7.2). The cells were resuspended in 20 ml of PBS-MACS and incubated for
20 min at RT with 40 µl of the gp350/220-specific mouse monoclonal
antibody mab-64D7. After the cells were washed twice with PBS-MACS,
they were resuspended in 800 µl of PBS-MACS and incubated for 15 min at RT with 200 µl of a suspension of magnetic beads (MACS system) conjugated with a mouse-immunoglobulin-specific monoclonal antibody. The cells were washed again, and 200 µl of a fluorescein
isothiocyanate-conjugated mouse-specific antibody was added and
incubated for 10 min at RT in the dark. Finally, the cells were applied
to a separation column (type RS+; Miltenyi Biotech) in the
magnetic field. The separation column was washed, and the
gp350/220-positive cells were eluted according to the manufacturer's
instructions. An aliquot of the purified cells could be used directly
for FACS analysis to check the purity. Chemical treatment of the cells
and subsequent purification resulted in an approximately 90% pure
population of cells in the late phase of lytic replication, positive
for the viral gp350/220 glycoprotein (Fig.
2B, upper right quadrant). Prior to the
purification, 62% of the cells in the culture were negative for this
late-lytic-cycle marker (Fig. 2A, lower right quadrant). A control
experiment with the EBV-negative cell line DG75 did not show any
significant difference in the signal for gp350/220 prior to and after
chemical treatment (Fig. 2C and D, respectively).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 2.
Purification of lytically infected gp350/220-positive
P3HR1/13 cells. P3HR1/13 cells were treated with TPA-BA-TGF- for
72 h. Lytically infected cells were labeled with the
gp350/220-specific mouse monoclonal antibody mab-64D7 and purified with
paramagnetic beads (MACS system), coated with a secondary anti-mouse
antibody, according to the manufacturer's instructions. The cells in
the upper right quadrant of each panel were considered positive; the
cells in the lower right quadrant were considered negative. (A) P3HR1
cells after 72 h of induction, prior to purification and (B) after
purification of gp350/220-positive cells. (C) DG75 cells after 72 h of induction, prior to purification and (D) after purification of
gp350/220-positive cells. The percentage of gp350/220-positive cells is
indicated in the panels. The x axis indicates forward light
scatter (FSC); the y axis indicates the intensity of
gp350/220-specific fluorescence (FL1).
|
|
Transcription of the EBER genes is downregulated during lytic
replication.
Regulation of gene expression is achieved by
different mechanisms affecting transcription, posttranscriptional
processing, degradation, and stability of the mRNA. Previous reports
investigating the expression of the EBERs in lytically infected
cultured cells by Northern blotting could not confirm the
downregulation observed in vivo. To avoid two problems that could mask
a regulation of the EBERs, the contamination of the lytically infected
cell population with latently infected cells and the presence of stable
EBERs produced during the preceding viral latency, we measured the
actual transcriptional activity of both EBER genes directly with
nuclear run-on experiments according to the methods of Greenberg and
Ziff (6) and Groudine et al. (7), with some
modifications (16, 17) (Fig.
3). Cells were treated to induce viral
lytic replication, and the gp350/220-positive ones were enriched and
used for in vitro nuclear run-on experiments. The radioactivity-labeled
RNA was hybridized to gene-specific DNA probes immobilized on membranes by Southern transfer. The gene-specific probes were synthesized by PCR
using the Powerscript polymerase (PAN Systems, Nürnberg, Germany). The probes for histone, EBNA-2, LMP-1, Rta (BRLF-1), and Zta
(BZLF-1) were designed to retain the intron-exon structure of the
respective genes since cDNA probes of the spliced transcripts showed
significantly lower hybridization signals. The genes for EBER-1,
EBER-2, EA (BALF-2), and VCA (BcLF-1) were free of introns owing to
their genomic organization. The sequences of primers were as follows:
EBER-1 and EBER-2, reference 22; Zta (BZLF-1), 5'-TGT CCA TGA ACC GGT CGG ATC-3' and 5'-GCG GTA AAC AAT GGC ACC CTC-3'; Rta (BRLF-1), 5'-GGC TTG GCT AAG TGC AAG GAT-3' and 5'-GGA GGA
GGC AGT TTT CAG AAG T-3'; EA (BALF-2), reference 14;
VCA (BcLF-1), reference 14; EBNA-2, 5'-CAA GCT GCT
TTG ATT CTT GGG-3' and 5'-GAG CTA CCT ACC ATG CTA TAA G-3'; LMP1,
5'-GGT TCA TCG CTC AGC TCC TCC-3' and 5'-CCT GAA TCC GCC ACC TCA
TTC-3'; histone, reference 4.

View larger version (69K):
[in this window]
[in a new window]
|
FIG. 3.
Analysis of viral gene activity in latent and lytically
infected cell lines by nuclear run-on experiments. The cell lines
Akata, B95-8, Raji, P3HR1/16, and P3HR1/13 (not shown here) were
treated for 72 h with TPA-BA-TGF- to induce lytic replication
of EBV. After 72 h, the nuclei were purified and nuclear run-on
experiments were performed. The radiolabeled RNA, reflecting the actual
gene activity, was hybridized to several immobilized gene-specific DNA
probes, and finally the membrane was exposed to X-ray film.
Gene-specific probes: lane 1, histone H3; lane 2, EBNA-2; lane 3, LMP-1; lane 4, EBER-1; lane 5, EBER-2; lane 6, BRLF-1 (Rta); lane 7, BZLF-1 (Zta); lane 8, BALF-2 (EA); lane 9, BcLF-1 (VCA). (A) Cells
prior to chemical induction. (B) Cells after 72 h of induction,
prior to purification. (C) Cells after 72 h of induction,
following purification of gp350/220-positive cells. (D) Akata cells
after 72 h of induction with anti-immunoglobulin G, without
purification. (E) P3HR1/16 cells after 72 h of induction with
TPA-BA-TGF- in the presence of PAA to inhibit viral DNA
replication.
|
|
In order to compare the variable transcriptional activities of the
genes between different experiments, the concentration
of gene-specific
probe(s), which quantitatively bind to and detect
the specific
transcripts, must be kept constant. In contrast to
Northern blot
assays, in run-on assays the constant parameter
(probes) was unlabelled
and was immobilized to a membrane. The
variable parameter (different
concentrations of various transcripts)
was labeled and was contained in
the hybridization solution. Since
in each run-on experiment a constant
number of nuclei (2 × 10
7) was used, the variable
amounts of
32P incorporated in the individual run-on
reactions reflected the
sum of variable transcriptional activities of a
vast number of
genes. This
32P-labeled RNA was
quantitatively used for hybridization to ensure
that the amount of
hybridization to the gene-specific probes directly
reflected the
genes' transcriptional activity. Differences in
hybridization due to
different efficiencies in individual run-on
experiments were precluded
by performing assays in parallel.
In the latently infected cell lines Akata, B95-8, Raji, and P3HR1/16
(Fig.
3A), we detected transcription of the latent genes
EBNA-2 (lane
2), LMP-1 (lane 3), and both EBER-1 and EBER-2 (lanes
4 and 5, respectively). After treatment with TPA, BA, and TGF-
(Fig.
3B) in
all the cell lines except Raji, transcription of
both the
immediate-early genes BRLF-1 and BZLF-1 (lanes 6 and
7, respectively)
and of early BALF-2 (lane 8) and late BcLF-1
(lane 9) was detected,
demonstrating a switch to lytic replication.
A significant reduction in
the rate of transcription, standardized
to the activity of the histone
gene as our internal control, was
detected for both EBER-1 (lane 4) and
EBER-2 (lane 5) in the cell
lines Akata (16% and 33%, respectively),
P3HR1/16 (9% and 23%,
respectively), and Raji (41% and 46%,
respectively). In addition,
downregulation of EBER-1 was more stringent
than that of EBER-2.
This was apparent from the EBER-1/EBER-2 ratio in
the cell lines
Akata (latent, 1.2; lytic, 0.6) and P3HR1/16 (latent,
1.2; lytic,
0.5), which showed the strongest overall repression of the
EBERs
compared to the histones. After purification of the
gp350/220-positive
P3HR1/16 cells in the late phase of lytic
replication, the effect
on the selective downregulation of EBER-1 and
on the EBER-1/EBER-2
ratio was nearly the same (latent, 1.2; lytic,
0.5; purified lytic,
0.7) (Fig.
3C). At first glance, the
downregulation of EBER-1
and EBER-2 relative to the expression of the
histones was not
as pronounced as that in unpurified cells (72% and
84%, respectively).
However, this effect was only relative, owing to
the downregulation
of the histone itself, probably because of the host
shutoff in
the late lytic phase of replication. The absolute
intensities
of the lytic cycle transcripts (lanes 6 to 9) and of the
EBERs
(lanes 4 and 5) remained rather constant, suggesting that
downregulation
of the EBERs and of histone happens independently.
Akata and B95-8 cells could not be enriched by the protocol described
above, although they showed a good induction of lytic
replication in
Western blot assays. This was probably a result
of the particular
property of the gp350/220-specific monoclonal
antibody mab-64D7,
recognizing the native membrane-bound glycoprotein
of the EBV strains
Akata and B95-8 less efficiently than that
of P3HR1. In contrast,
recognition of the partially denatured
protein by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis
and Western blotting was
comparable, demonstrating similar induction
of lytic replication in
Akata cells (not shown).
In order to show that downregulation of the EBERs did not depend on TPA
treatment, Akata cells were incubated for 72 h with
anti-immunoglobulin G antibodies (Fig.
3D). These cells showed
a
comparable pattern of downregulation of both EBER-1 and EBER-2
(31%
and 60%, respectively; EBER-1/EBER-2 ratio, 0.6).
The amount of EBER transcripts in the cell remained constant after
induction of lytic virus replication.
Our nuclear run-on
experiments clearly demonstrated a downregulation of the transcription
of the EBER genes. Therefore we investigated whether the difference
from earlier reports demonstrating continuous expression of both EBERs
in cell culture was due to a different experimental design, detecting
the rather stable EBERs with a long half-life synthesized during viral
latency. We asked whether the downregulation of EBER could also be
detected at the level of RNA transcripts or whether the amount of EBERs
would remain unaffected within the first 72 h after induction of
lytic replication. From the same batch of stimulated P3HR1 cells used for the nuclear run-on experiments described above, RNA was prepared prior to the separation of the lytically infected cells and used for
Northern blot and reverse transcriptase PCR (RT-PCR) analysis. For
Northern blot analysis the gene-specific probes for EBER-1, EBER-2, and
histone were synthesized by RT-PCR with total RNA from B95-8 cells. The
probes for Northern blots were radiolabeled with
[
-32P]dATP during the reamplification PCR. As shown in
Fig. 4, there was no difference in the
concentration of EBERs between the latent and the stimulated cell
lines Akata (lanes 2 and 6), B95-8 (lanes 3 and 7), P3HR1/16 (lanes 4 and 8), and P3HR1/13 (lanes 5 and 9), assayed by either Northern
blotting (Fig. 4) or RT-PCR (data not shown). With the same
unfractionated population of cells, however, nuclear run-on assays
showed significant downregulation of transcription of the EBER-1 and
EBER-2 genes (Fig. 3). Thus, these experiments demonstrated that
regulation of the EBERs during the initial 72 h after induction of
lytic virus replication could be detected only at the level of
transcription, due to the long half-life of the EBERs.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 4.
Quantification of EBER transcripts in latent and
lytically infected P3HR1/13 cells by Northern blot analysis. The cell
lines Akata, B95-8, P3HR1/16, and P3HR1/13 were treated for 72 h
with TPA-BA-TGF- to induce lytic replication of EBV. After 72 h, total RNA was purified and Northern blot experiments were performed.
Hybridization of the immobilized RNA was done with (A) EBER-1-specific,
(B) EBER-2-specific, or (C) histone H3-specific (control for RNA)
radiolabeled probes. Cell lines: lanes 1 and 6, Akata; lanes 2 and 7, B95-8; lanes 3 and 8; P3HR1/13; lanes 4 and 9, P3HR1/16. Lanes 1 to 5:
latent cells; lanes 6 to 9: chemically treated cells.
|
|
Downregulation of EBER-1 and EBER-2 are early events during lytic
replication of EBV.
Detection of downregulation of the EBERs in
unfractionated cell populations was unexpected due to the large
percentage of gp350/220-negative cells, which were supposed to be
latently infected and produce huge quantities of EBER-1 and EBER-2.
Therefore we tested whether the downregulation may be an early event
during the switch from latency to lytic replication of EBV. With
nuclear run-on experiments we assayed transcription of the EBERs in
P3HR1 cells, which were treated with TPA, BA, and TGF-
in
combination with phosphonoacetic acid (PAA) to induce the lytic phase
but block viral DNA replication (Fig. 3E). It could be shown that both
EBER genes were downregulated (13% EBER-1 and 13% EBER-2) in this
experimental approach when their activity was compared with the
activity of the histone gene. The same results were obtained with the
cell line Raji (Fig. 3B), which is blocked in the early phase of
replication by a mutation (41% EBER-1 and 46% EBER-2). Transcripts of
the immediate-early genes BZLF-1 and BRLF-1 were induced, whereas the
late gene BcLF-1 was kept silent. The EBER-1/EBER-2 ratios remained
unaltered in both P3HR-1/16 (latent, 1.2; lytic, 1.0) and Raji (latent,
1.3; lytic, 1.1) cells. These experiments clarified that the
downregulation of EBER-1 is an early event in the lytic replication of
EBV, probably directly regulated by cellular factors.
With this paper we demonstrate that during the phase of lytic
replication transcription of EBER-1 is dramatically downregulated,
as
is, to a minor extent, transcription of EBER-2. This could
not be
reproduced experimentally in cell culture so far. Furthermore,
we
demonstrate that, in contrast to transcription, the amount
of the EBERs
remains unaltered within 72 h after induction of
lytic
replication, which may explain the previous incongruent
reports. The
difference in the detection of the EBERs in induced
cultured cells and
the absence in epithelial cells observed in
vivo may be explained by
the half-life of the EBERs. Seventy-two
hours is obviously not
sufficient time to degrade the EBERs produced
during latency, showing
that the half-lives of the EBERs are significantly
prolonged in the
lytic phase of viral replication compared with
8 to 9 h in latent
infection (
2). A study by Pathmanathan et
al.
(
13) showed the absence of EBER expression in vivo in areas
of tissue differentiation. A study of an EBV-positive lymphoma
that
developed in a salivary gland showed permissive replication
in
epithelial cells adjacent to the lymphoma with expression of
BZLF-1
without EBERs and expression of EBERs and LMP-1 in the
lymphoma tissue
(
25). These studies suggest that differentiation
may
negatively regulate EBER expression. Differences in epithelial
infection versus lymphoid infection and differences in differentiation
status may explain the lack of EBER expression in in vivo infection
compared with the situation after reactivation of EBV replication
in
lymphocytes.
The observed differential regulation of EBER-1 and EBER-2 did not
directly reveal a new role of these RNAs in the life cycle
of the
virus. However, these results suggested that EBER-1 may
have a function
different from that of EBER-2. Previous reports
with recombinant
EBER-negative mutant EBV demonstrated that neither
gene is necessary
for latency nor for the lytic replication of
the virus in cell culture.
Now, the downregulation of the EBERs
is suggestive of a function that
may be incompatible with lytic
replication and thus may be involved in
stabilizing viral latency,
which is in accordance with the early
regulation during the lytic
cycle. Recently, we have described a case
of chronic active infection
with EBV. With a semiquantitative RT-PCR we
detected expression
of the immediate-early gene BZLF-1 in the B
lymphocytes of the
patient in an amount characteristic of primary
infection, which
is associated with complete lytic replication of EBV
in the B
cells of the peripheral blood (
14). Remarkably,
with in situ
hybridization no EBER transcripts were detected in those B
cells
although EBV DNA was found (
12).
Finally, the direct effect of downregulation of the transcription of
the EBER genes still remains unclear, since the concentration
of the
EBER-1 RNA and probably of EBER-2 RNA is unaffected. One
possible
explanation is that the EBERs detected during the lytic
replication of
EBV are not functional anymore. However, as long
as the function of the
EBERs is not clear, this will be difficult
to test. Several parameters
that may influence the function of
an RNA are under investigation.
 |
ACKNOWLEDGMENTS |
We are grateful to Sabine Richter for critically reading the
manuscript.
This work was supported by the Deutsche Forschungsgemeinschaft (grants
Wo227/6 and Wo227/7 V).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institut
für Medizinische Mikrobiologie und Hygiene,
Universität Regensburg, Franz-Josef-Strauss-Allee 11, D-93053
Regensburg, Germany. Phone: 49 941 9446452. Fax: 49 941 944 6402. E-mail:
Fritz.Schwarzmann{at}klinik.uni-regensburg.de.
 |
REFERENCES |
| 1.
|
Bauer, G.,
P. Hofler, and H. zur Hausen.
1982.
Epstein-Barr virus induction by a serum factor. I. Induction and cooperation with additional inducers.
Virology
121:184-194[Medline].
|
| 2.
|
Clarke, P. A.,
N. A. Sharp, and M. J. Clemens.
1992.
Expression of genes for the Epstein-Barr virus small RNAs EBER-1 and EBER-2 in Daudi Burkitt's lymphoma cells: effects of interferon treatment.
J. Gen. Virol.
73:3169-3175[Abstract/Free Full Text].
|
| 3.
|
Clemens, M. J.
1994.
Functional significance of the Epstein-Barr virus-encoded small RNAs.
Epstein-Barr Virus Rep.
5:107-111.
|
| 4.
|
Futscher, B. W.,
L. L. Blake,
J. H. Gerlach,
T. M. Grogan, and W. S. Dalton.
1993.
Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens.
Anal. Biochem.
213:414-421[Medline].
|
| 5.
|
Gilligan, K.,
P. Rajadurai,
L. Resnick, and N. Raab Traub.
1990.
Epstein-Barr virus small nuclear RNAs are not expressed in permissively infected cells in AIDS-associated leukoplakia.
Proc. Natl. Acad. Sci. USA
87:8790-8794[Abstract/Free Full Text].
|
| 6.
|
Greenberg, M. E., and E. B. Ziff.
1984.
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene.
Nature
311:433-438[Medline].
|
| 7.
|
Groudine, M.,
M. Peretz, and H. Weintraub.
1981.
Transcriptional regulation of hemoglobin switching in chicken embryos.
Mol. Cell. Biol.
1:281-288[Abstract/Free Full Text].
|
| 8.
|
Hironaka, T.,
M. Nagasaki,
S. Morikawa, and K. Hirai.
1993.
Detection of Epstein-Barr virus transcripts in chemically or immunologically-activated cells and in a null cell-line (HLN-STL-C) by in situ hybridization with alkaline phosphatase-linked oligonucleotide probes.
J. Virol. Methods
44:141-154[Medline].
|
| 9.
|
Howe, J. G., and M.-D. Shu.
1989.
Epstein-Barr virus small RNA (EBER) genes: unique transcription units that combine RNA polymerase II and III promoter elements.
Cell
57:825-834[Medline].
|
| 10.
|
Howe, J. G., and J. A. Steitz.
1986.
Localization of Epstein-Barr virus-encoded small RNAs by in situ hybridization.
Proc. Natl. Acad. Sci. USA
83:9006-9010[Abstract/Free Full Text].
|
| 11.
|
Lerner, M. R.,
N. C. Andrews,
G. Miller, and J. A. Steitz.
1981.
Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus.
Proc. Natl. Acad. Sci. USA
78:805-809[Abstract/Free Full Text].
|
| 12.
|
Mitterer, M.,
N. Pescosta,
F. Fend,
C. Larcher,
N. Prang,
F. Schwarzmann,
P. Coser, and H. P. Huemer.
1995.
Chronic active Epstein-Barr virus disease in a case of persistent polyclonal B-cell lymphocytosis.
Br. J. Haematol.
90:526-531[Medline].
|
| 13.
|
Pathmanathan, R.,
U. Prasad,
G. Chandrika,
R. Sadler,
K. Flynn, and N. Raab-Traub.
1995.
Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia.
Am. J. Pathol.
146:1355-1367[Abstract].
|
| 14.
|
Prang, N. S.,
M. W. Hornef,
M. Jäger,
W. J. Wagner,
H. Wolf, and F. Schwarzmann.
1997.
Lytic replication of Epstein-Barr virus in the peripheral blood: analysis of viral gene expression in B-lymphocytes during infectious mononucleosis and in the normal carrier state.
Blood
89:1665-1677[Abstract/Free Full Text].
|
| 15.
|
Rosa, M. D.,
E. Gottlieb,
M. R. Lerner, and J. A. Steitz.
1981.
Striking similarities are exhibited by two small Epstein-Barr virus-encoded ribonucleic acids and the adenovirus-associated ribonucleic acids VAI and VAII.
Mol. Cell. Biol.
1:785-796[Abstract/Free Full Text].
|
| 16.
|
Schwarzmann, F.,
M. Jäger,
N. Prang, and H. Wolf.
1998.
The control of lytic replication of Epstein-Barr virus in B lymphocytes.
Int. J. Mol. Med.
1:137-142[Medline].
|
| 17.
|
Schwarzmann, F.,
N. Prang,
B. Reichelt,
B. Rinkes,
S. Haist,
M. Marschall, and H. Wolf.
1994.
Negative cis-acting elements in the distal part of the promoter of Epstein-Barr virus trans-activator gene BZLF1.
J. Gen. Virol.
75:1999-2006[Abstract/Free Full Text].
|
| 18.
|
Schwemmle, M.,
M. J. Clemens,
K. Hilse,
K. Pfeifer,
H. Troster,
W. E. Muller, and M. Bachmann.
1992.
Localization of Epstein-Barr virus-encoded RNAs EBER-1 and EBER-2 in interphase and mitotic Burkitt lymphoma cells.
Proc. Natl. Acad. Sci. USA
89:10292-10296[Abstract/Free Full Text].
|
| 19.
|
Sharp, T. V.,
M. Schwemmle,
I. Jeffrey,
K. Laing,
H. Mellor,
C. G. Proud,
K. Hilse, and M. J. Clemens.
1993.
Comparative analysis of the regulation of the interferon-inducible protein kinase PKR by Epstein-Barr virus RNAs EBER-1 and EBER-2 and adenovirus VAI RNA.
Nucleic Acids Res.
21:4483-4490[Abstract/Free Full Text].
|
| 20.
|
Swaminathan, S.,
B. S. Huneycutt,
C. S. Reiss, and E. Kieff.
1992.
Epstein-Barr virus-encoded small RNAs (EBERs) do not modulate interferon effects in infected lymphocytes.
J. Virol.
66:5133-5136[Abstract/Free Full Text].
|
| 21.
|
Swaminathan, S.,
B. Tomkinson, and E. Kieff.
1991.
Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro.
Proc. Natl. Acad. Sci. USA
88:1546-1550[Abstract/Free Full Text].
|
| 22.
|
Tierney, R. J.,
N. Steven,
L. S. Young, and A. B. Rickinson.
1994.
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.
J. Virol.
68:7374-7385[Abstract/Free Full Text].
|
| 23.
|
Toczyski, D. P.,
A. G. Matera,
D. C. Ward, and J. A. Steitz.
1994.
The Epstein-Barr virus (EBV) small RNA EBER1 binds and relocalizes ribosomal protein L22 in EBV-infected human B lymphocytes.
Proc. Natl. Acad. Sci. USA
91:3463-3467[Abstract/Free Full Text].
|
| 24.
|
Weigel, R.,
D. K. Fischer,
L. Heston, and G. Miller.
1985.
Constitutive expression of Epstein-Barr virus-encoded RNAs and nuclear antigen during latency and after induction of Epstein-Barr virus replication.
J. Virol.
53:254-259[Abstract/Free Full Text].
|
| 25.
|
Wen, S.,
Y. Mizugaki,
F. Shinozaki, and K. Takada.
1997.
Epstein-Barr virus (EBV) infection in salivary gland tumors: lytic EBV infection in nonmalignant epithelial cells surrounded by EBV-positive T-lymphoma cells.
Virology
227:484-487[Medline].
|
| 26.
|
Zeuthen, J.
1983.
Epstein-Barr virus (EBV), lymphocytes and transformation.
J. Cancer Res. Clin. Oncol.
106:1-11.
|
Journal of Virology, November 1998, p. 9323-9328, Vol. 72, No. 11
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Felton-Edkins, Z. A., Kondrashov, A., Karali, D., Fairley, J. A., Dawson, C. W., Arrand, J. R., Young, L. S., White, R. J.
(2006). Epstein-Barr Virus Induces Cellular Transcription Factors to Allow Active Expression of EBER Genes by RNA Polymerase III. J. Biol. Chem.
281: 33871-33880
[Abstract]
[Full Text]
-
Ruf, I. K., Lackey, K. A., Warudkar, S., Sample, J. T.
(2005). Protection from Interferon-Induced Apoptosis by Epstein-Barr Virus Small RNAs Is Not Mediated by Inhibition of PKR. J. Virol.
79: 14562-14569
[Abstract]
[Full Text]
-
Huang, J., Chen, H., Hutt-Fletcher, L., Ambinder, R. F., Hayward, S. D.
(2003). Lytic Viral Replication as a Contributor to the Detection of Epstein-Barr Virus in Breast Cancer. J. Virol.
77: 13267-13274
[Abstract]
[Full Text]
-
DUMPELMANN, E., MITTENDORF, H., BENECKE, B.-J.
(2003). Efficient transcription of the EBER2 gene depends on the structural integrity of the RNA. RNA
9: 432-442
[Abstract]
[Full Text]
-
Poppers, J., Mulvey, M., Perez, C., Khoo, D., Mohr, I.
(2002). Identification of a Lytic-Cycle Epstein-Barr Virus Gene Product That Can Regulate PKR Activation. J. Virol.
77: 228-236
[Abstract]
[Full Text]
-
Wensing, B., Stuhler, A., Jenkins, P., Hollyoake, M., Karstegl, C. E., Farrell, P. J.
(2001). Variant Chromatin Structure of the oriP Region of Epstein-Barr Virus and Regulation of EBER1 Expression by Upstream Sequences and oriP. J. Virol.
75: 6235-6241
[Abstract]
[Full Text]